♟️ Monday 27 July 2026 Mon, 27 July 2026

Prescient Therapeutics boosted enrolment in its PTX-100 Phase 2a trial to 28 patients and appointed Dr Rosalind Wilson as Chief Medical Officer, strengthening its clinical leadership as it advances targeted cancer therapies.

Arovella Therapeutics secured ethics approval and manufactured its first clinical batch of ALA-101, targeting blood cancers, while progressing its solid tumour program and refining autoimmune strategies. The company ended the quarter with $14.4 million in cash, supporting imminent clinical milestones.

Sena & Co, already holding 75.9% of 2 Cheap Cars, proposes a full takeover at NZ$0.80 per share, aiming to delist the company and compulsorily acquire remaining shares.

Minerals Exploration Limited has completed its first phase of diamond drilling at the historic Jubilee Gold Mine within the Waitekauri Gold Project, confirming multiple quartz-mineralised zones and exceptional high-grade rock chip assays. Exploration continues with promising results at the Invincible Gold and Glenorchy Tungsten projects.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.

Imugene's azer-cel therapy shows a third patient response in the BTKi combination cohort of its Phase 1b trial, while CEO Leslie Chong steps down after nearly 11 years, prompting a leadership search.

West Wits Mining has achieved a major underground breakthrough at Qala Shallows, unlocking higher-grade ore zones, while completing a comprehensive ZAR 1.115 billion finance package that underpins its production ramp-up.

Noronex Ltd has secured a major foothold in the US critical minerals sector by acquiring the Sleitat Tin-Tungsten-Silver Project in Alaska, featuring a substantial historic tin estimate and promising exploration upside.

AML3D Limited closed FY26 with a record $29 million order book, driven by US defence contracts and a $12 million investment to double its Ohio manufacturing capacity. The company’s cash receipts rose 20% to $10.4 million, while its sales pipeline expanded to $78 million.

Firebrick Pharma expanded its patent portfolio with grants in Canada and New Zealand while achieving 43% sales growth in FY26 despite steady operating expenses. The company is advancing Nasodine's commercial rollout across Southeast Asia and the US.

Electro Optic Systems (ASX:EOS) posted a 284% surge in first-half 2026 revenue to $169 million, driven by robust defence contracts and regional tensions. Its order book hit a historic $846 million, prompting an upgrade to full-year guidance and signalling strong momentum in counter-drone and laser weapon systems.

Anax Metals has kicked off Front-End Engineering Design for its Whim Creek Copper Project, setting the stage for a Final Investment Decision by the end of 2026. The project, boasting a robust DFS with a pre-tax NPV7 of A$501 million and a 98% IRR, moves closer to construction amid ongoing financing talks.

Torque Metals has boosted its Paris Gold Project resource by 40% to 351,000 ounces at 3.1g/t gold, underpinning an ambitious new growth strategy, Project RPM, aimed at rapidly expanding its South Kalgoorlie Gold Camp to a 1 million ounce high-grade resource.

Conrad Asia Energy has locked in over 90% of its US$320 million Mako Gas Project contracts, maintaining its timeline for first gas in late 2027 while restructuring leadership and progressing Aceh PSC assets.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.

Prodigy Gold’s latest scoping study for the Hyperion Gold Project outlines a viable open pit operation with a 260,000-ounce production target and strong financial metrics. Meanwhile, exploration funding and ore sorting advances at Old Pirate support near-term development prospects.

Evolution Mining (ASX: EVN) is set to acquire Carnaby Resources (ASX: CNB) in a $213 million deal that expands its copper production pipeline near Ernest Henry, leveraging existing infrastructure and latent mill capacity.

Evolution Mining has agreed to acquire Carnaby Resources via a scheme of arrangement valuing Carnaby at around A$213 million, delivering a 60% premium to shareholders and aiming to de-risk the Greater Duchess project.

Delta Lithium delivered high-grade lithium drilling results at Mt Ida and uncovered significant fluorite mineralisation at Yinnetharra, while securing key tenement acquisitions and maintaining a strong cash position of $49.6 million.

ClearView Wealth held a pivotal Scheme Meeting, securing strong shareholder backing for Zurich's $0.65-per-share acquisition offer, with the board and independent expert endorsing the deal as fair and beneficial.

Imricor Medical Systems has officially launched its US commercial operations, securing Rady Children’s Hospital–San Diego as the first customer for its NorthStar iMR mapping system, following key FDA clearances including pediatric approvals.

Adherium reports a near tenfold surge in recurring revenue from remote patient monitoring and clinical evidence supporting significant cost reductions in respiratory care.

Kali Metals has completed its Phase II drilling at Marble Bar, confirming gold mineralisation continuity and identifying four new high-grade gold prospects, while maintaining a strong cash position of $6.84 million.